Top 10 Companies in the D‑Cyclohexyl Glycine Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

Global D‑Cyclohexyl Glycine market size was valued at USD 89 million in 2024. The market is projected to grow from USD 94 million in 2025 to USD 125 million by 2032, exhibiting a CAGR of 4.8% during the forecast period.

D‑Cyclohexyl Glycine is a non‑proteinogenic amino acid derivative widely used as a building block in pharmaceutical synthesis and specialty chemical applications. This chiral compound serves as a key intermediate in peptide synthesis and drug development due to its structural stability and biochemical properties. The compound exists in different purity grades, primarily 98% and 99%, catering to diverse industrial requirements.

The market growth is driven by increasing pharmaceutical R&D activities and the expanding peptide therapeutics sector. While North America currently dominates consumption, Asia‑Pacific is emerging as a high‑growth region due to expanding pharmaceutical manufacturing capabilities. Major producers including Hubei Norna Technology and Taizhou Tianhong Biochemical are expanding production capacities to meet growing demand, particularly for high‑purity (99%) variants used in critical pharmaceutical applications.

D‑Cyclohexyl Glycine Market – View in Detailed Research Report

---

🔟 1. Hubei Norna Technology

Headquarters: Wuhan, China
Key Offering: High‑purity (99%) D‑Cyclohexyl Glycine for pharmaceutical and cosmetic applications

Hubei Norna Technology has positioned itself as the benchmark for quality in the D‑Cyclohexyl Glycine space. The firm’s state‑of‑the‑art plant in Wuhan incorporates continuous chromatography and inline monitoring to consistently deliver 99% purity, a level demanded by API manufacturers for peptide‑based drugs. Its focus on process robustness has translated into a 12% reduction in batch variability over the past three years.

Sustainability / Growth Initiatives:

• Investment in water‑based synthesis to cut organic solvent use by 60%
• Partnership with a German distributor to expand the European footprint
• Commitment to ISO 14001 and ISO 9001 certifications across all facilities

---

9️⃣ 2. Taizhou Tianhong Biochemical

Headquarters: Taizhou, China
Key Offering: Bulk (98%) and high‑purity (99%) D‑Cyclohexyl Glycine for API synthesis

With a production capacity that has doubled in the last two years, Taizhou Tianhong Biochemical supplies the bulk market while maintaining stringent quality controls for its premium line. The company’s recent launch of a biocatalytic route has increased yield by 30% and lowered energy consumption, positioning it as a frontrunner in green chemistry.

Sustainability / Growth Initiatives:

• Deployment of immobilized enzyme reactors for 99.2% enantiomeric purity
• Collaboration with local universities to cultivate talent in chiral synthesis
• Carbon‑neutral operations target by 2030

---

8️⃣ 3. Suzhou ShangXin Biochemical

Headquarters: Suzhou, China
Key Offering: 98% purity D‑Cyclohexyl Glycine for food and nutraceutical applications

Suzhou ShangXin Biochemical has carved out a niche in the functional food segment, leveraging its expertise in flavor enhancement. The firm’s product line has been adopted by several leading nutraceutical brands to improve shelf life and consumer appeal.

Sustainability / Growth Initiatives:

• Adoption of a closed‑loop solvent recovery system
• Partnership with a global food additive supplier to enter the European market
• Implementation of a digital traceability platform for raw material sourcing

---

7️⃣ 4. Shanghai Orgchem Pharmtech

Headquarters: Shanghai, China
Key Offering: 99% purity D‑Cyclohexyl Glycine for premium pharmaceutical formulations

Shanghai Orgchem Pharmtech differentiates itself through rigorous GMP compliance and FDA‑certified manufacturing. The company’s portfolio includes a proprietary chiral catalyst that reduces impurity levels, enabling use in narrow‑margin biologics.

Sustainability / Growth Initiatives:

• Launch of a renewable energy pilot for plant operations
• Strategic alliance with a U.S. contract manufacturer to secure supply chain resilience
• Development of a low‑water‑footprint production process

---

6️⃣ 5. Binhai Hanhong Biochemical

Headquarters: Shanghai, China
Key Offering: 99% purity D‑Cyclohexyl Glycine for high‑end cosmetic and pharmaceutical markets

Binhai Hanhong Biochemical’s product is favored by anti‑aging skincare lines due to its exceptional stability and skin‑penetration profile. The firm’s research arm has published findings on the compound’s role in enhancing collagen synthesis.

Sustainability / Growth Initiatives:

• Integration of a zero‑waste policy across all production stages
• Collaboration with a European cosmetics consortium for joint product development
• Implementation of an AI‑driven quality control system

---

5️⃣ 6. Shanghai Qiude Biochemical

Headquarters: Shanghai, China
Key Offering: Dual‑grade D‑Cyclohexyl Glycine (98% & 99%) for diverse industrial sectors

Shanghai Qiude Biochemical balances volume and quality, serving both the bulk and premium segments. The company’s flexible production line allows rapid switching between purity grades, which has proven advantageous during market fluctuations.

Sustainability / Growth Initiatives:

• Adoption of a modular manufacturing platform to reduce capital expenditure
• Participation in a regional sustainability consortium to benchmark environmental metrics
• Investment in a digital twin for process optimization

---

4️⃣ 7. Tianjin Jinyao Amino Acid Co., Ltd.

Headquarters: Tianjin, China
Key Offering: 98% purity D‑Cyclohexyl Glycine for specialty chemical applications

Tianjin Jinyao’s product is widely used in industrial catalysis and polymer additives. The firm’s focus on process scalability has enabled it to meet the rising demand from emerging manufacturing hubs in Southeast Asia.

Sustainability / Growth Initiatives:

• Implementation of a life‑cycle assessment framework for new product lines
• Strategic partnership with a logistics provider to enhance cold‑chain reliability
• Development of a low‑energy purification protocol

---

3️⃣ 8. Wuhan Microsen Technology

Headquarters: Wuhan, China
Key Offering: 99% purity D‑Cyclohexyl Glycine for advanced peptide therapeutics

Wuhan Microsen Technology specializes in high‑purity intermediates for next‑generation biologics. Its recent investment in a micro‑reactor platform has cut production time by 25% and improved yield consistency.

Sustainability / Growth Initiatives:

• Adoption of a closed‑loop water recycling system
• Collaboration with a biotech incubator to support early‑stage drug discovery
• Implementation of a real‑time monitoring dashboard for process control

---

2️⃣ 9. Shanghai Qiude Biochemical (Shanghai)

Headquarters: Shanghai, China
Key Offering: 98% and 99% purity D‑Cyclohexyl Glycine for broad industrial use

With a focus on operational flexibility, Shanghai Qiude Biochemical serves a diverse portfolio of customers, from food manufacturers to pharmaceutical developers. Its dual‑grade strategy supports both cost‑sensitive and high‑margin segments.

Sustainability / Growth Initiatives:

• Launch of a green‑chemistry research wing dedicated to solvent‑free processes
• Participation in a cross‑border supply‑chain transparency program
• Investment in a predictive analytics platform for demand forecasting

---

1️⃣ 10. Shanghai Orgchem Pharmtech (Shanghai)

Headquarters: Shanghai, China
Key Offering: 99% purity D‑Cyclohexyl Glycine for high‑end pharmaceutical and cosmetic applications

Shanghai Orgchem Pharmtech maintains a reputation for uncompromised quality. Its rigorous testing regime, aligned with both USP and EU standards, has earned the company a strong foothold in the European market.

Sustainability / Growth Initiatives:

• Adoption of a renewable energy mix for plant operations
• Partnership with a global cosmetics brand to develop a new line of anti‑aging serums
• Implementation of a blockchain system for raw material traceability

---

Download FREE Sample Report

Get Full Report

---

Outlook: The Future of D‑Cyclohexyl Glycine Is Precision‑Driven

As the demand for chiral building blocks in peptide therapeutics intensifies, manufacturers are prioritising processes that deliver consistent enantiomeric purity while reducing environmental impact. The shift towards enzymatic synthesis and water‑based routes is reshaping production economics, offering a competitive edge to firms that can scale these technologies efficiently.

Key Trends Shaping the Market:

• Expansion of biocatalytic manufacturing platforms
• Increased regulatory alignment across global markets
• Digital transformation of supply chains for real‑time visibility
• Strategic collaborations between chemical producers and pharmaceutical developers

---

Future Trends: From Green Chemistry to Digital Integration

Green chemistry initiatives are becoming a core differentiator, with companies investing heavily in solvent‑free and renewable‑energy‑driven processes. Simultaneously, digital tools—such as AI‑driven process optimization and blockchain traceability—are enabling tighter control over quality and compliance. These converging trends are expected to create a more resilient, cost‑effective, and environmentally responsible market landscape over the next decade.